Anti-aging Pill Challenged

Former biotech executive files lawsuit accusing the company of engaging in deceptive business practices.

By | July 31, 2012


Telomeres, the nucleotide sequences that protect chromosome ends from degradation, have been linked to aging as they shorten during every cell division. In 2005, the New York-based Telomerase Activation Sciences (TA Sciences) created a dietary supplement they claimed could lengthen shortened telomeres. The pill, named TA-65, brings in $6 million in annual US sales. Now, former TA Sciences Vice President for Global Sales Brian Egan has filed a class-action lawsuit against the company, challenging the supplement’s scientific basis, including the claim that TA-65 can lengthen telomeres. The president of TA Sciences, Noel Patton, denies all allegations.

Egan isn’t the first to be skeptical. “A compound that can lengthen telomeres would be excellent,” Carol Greider, who shared the Nobel Prize for her work on telomeres told Nature, but “we would need to test it rigorously.” Research sponsored by TA Sciences has shown the active ingredient, isolated from the herb Astragalus membranaceus does increase telomere length in mice and humans, but Greider and others have raised questions about the  methods used in the research, which was conducted by Telomere Health in Menlo Park, California. If the claims are true, it could be a huge boon to patients dying of bone marrow failure and pulmonary fibrosis, Greider told Nature.

Greider is also suspicious of the fact that TA Sciences sells the pill as nutritional supplement, rather than a drug.  As a supplement, the pill's health claims do not have to be evaluated by the FDA, nor do they have to be proven with extensive clinical trials in humans. However, Calvin Harley, president of Telomere Heath stands by the conclusion that TA-65 is a “weak telomerase activator.”

Starting in May 2011, Egan said he was required to take TA-65, in order to help expand TA Science's reach in foreign markets. Soon after, Egan was diagnosed with prostate cancer.  In September 2011, he was fired and was allegedly offered a cash settlement to keep his disease under wraps.  According to an affidavit filed by Patton, taking the product was not mandatory, and Egan was fired for bad sales.

In March 2012, TA Sciences sued Egan for telling a potential business partner that he had developed the cancer while taking TA-65. TA Sciences say they believe Egan already had the cancer before they hired him in May 2011. Egan filed his class-action lawsuit on 23 July 2012, in the New York State Supreme Court, along with another man who took TA-65.

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo


July 10, 2013

No adverse events?  Baloney, they are being sued in class actions and personal lawsuits,  and Noel Patton has a racial and sexual discrimination lawsuit against him personally.


Geron parting  ways with this guy  is very telling!

Avatar of: Honest Man

Honest Man

Posts: 1

August 24, 2014

It's really simple to settle this. Show some actual telemere tests that show improvement. After all that is what TA Sciences is claiming their product will do. Just show the tests. But I find that NOWHERE do that have the results of very simple telemere tests showing any acutal improvement. 

This is more telling than any personal testimonies etc.

If you claim you can lengthen telemeres then prove it. It is really a simple test.

I personally think they have run the tests but there was no improvement and that is why they NEVER show any actual telemere results.

Avatar of: SJ1948


Posts: 1

February 19, 2015

TA actually won this.


Popular Now

  1. A Newly Identified Species Represents Its Own Eukaryotic Lineage
  2. Telomere Length and Childhood Stress Don’t Always Correlate
  3. Optogenetic Therapies Move Closer to Clinical Use
  4. Research Links Gut Health to Neurodegeneration
    The Nutshell Research Links Gut Health to Neurodegeneration

    Rodent studies presented at the Society for Neuroscience meeting this week tie pathologies in the gastrointestinal tract or microbiome composition with Parkinson’s and Alzheimer’s diseases.